immatics biotechnologies GmbH - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 35

immatics biotechnologies GmbH – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “immatics biotechnologies GmbH - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- immatics biotechnologies GmbH - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of immatics biotechnologies GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of immatics biotechnologies GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the immatics biotechnologies GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate immatics biotechnologies GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with immatics biotechnologies GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas.

List of Tables
List of Figures
immatics biotechnologies GmbH Snapshot
immatics biotechnologies GmbH Overview
Key Information
Key Facts
immatics biotechnologies GmbH – Research and Development Overview
Key Therapeutic Areas
immatics biotechnologies GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
immatics biotechnologies GmbH – Pipeline Products Glance
immatics biotechnologies GmbH Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
immatics biotechnologies GmbH–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
immatics biotechnologies GmbH – Drug Profiles
IMA901
Product Description
Mechanism of Action
R&D Progress
IMA910
Product Description
Mechanism of Action
R&D Progress
IMA910 + Leukine
Product Description
Mechanism of Action
R&D Progress
IMA950
Product Description
Mechanism of Action
R&D Progress
IMA950
Product Description
Mechanism of Action
R&D Progress
IMA9xx
Product Description
Mechanism of Action
R&D Progress
immatics biotechnologies GmbH – Pipeline Analysis
immatics biotechnologies GmbH – Pipeline Products by Therapeutic Class
immatics biotechnologies GmbH - Pipeline Products By Target
immatics biotechnologies GmbH – Pipeline Products by Route of Administration
immatics biotechnologies GmbH – Pipeline Products by Molecule Type
immatics biotechnologies GmbH – Recent Pipeline Updates
immatics biotechnologies GmbH – Locations And Subsidiaries
Head Office
Financial Deals Landscape
immatics biotechnologies GmbH, Deals Summary, 2004 to 2011
immatics biotechnologies GmbH Detailed Deal Summary
Venture Financing
Immatics Biotechnologies Secures $51.96 Million In Series B Financing
immatics biotechnologies Secures $10.48 Million In First Round Of Venture Financing
immatics biotechnologies Enters Into Research Agreement With responsif
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
immatics biotechnologies GmbH – Pipeline by Therapy Area and Indication, 2011
immatics biotechnologies GmbH – Pipeline by Stage of Development, 2011
immatics biotechnologies GmbH – Monotherapy Products in Pipeline, 2011
immatics biotechnologies GmbH – Combination Treatment Modalities in Pipeline, 2011
immatics biotechnologies GmbH - Phase II, 2011
immatics biotechnologies GmbH - Phase I, 2011
immatics biotechnologies GmbH - Pipeline By Therapeutic Class, 2011
immatics biotechnologies GmbH - Pipeline By Target, 2011
immatics biotechnologies GmbH – Pipeline By Route of Administration, 2011
immatics biotechnologies GmbH – Pipeline By Molecule Type, 2011
immatics biotechnologies GmbH – Recent Pipeline Updates, 2011
immatics biotechnologies GmbH, Deals Summary, 2004 to 2011

List of Figures
immatics biotechnologies GmbH – Pipeline by Therapy Area and Indication, 2011
immatics biotechnologies GmbH – Pipeline by Stage of Development, 2011
immatics biotechnologies GmbH – Monotherapy Products in Pipeline, 2011
immatics biotechnologies GmbH – Combination Treatment Modalities in Pipeline, 2011
immatics biotechnologies GmbH – Pipeline By Therapeutic Class, 2011
immatics biotechnologies GmbH - Pipeline By Target, 2011
immatics biotechnologies GmbH – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• Accenture - Profile - US